Patient-reported outcomes (PROS) in patients switching to teriflunomide from a prior disease-modifying therapy (DMT): Results from the phase 4 teri-pro study

Authors
Category Primary study
JournalNeurology
Year 2017
This article has no abstract
Epistemonikos ID: aeeec135d93d7fd9c3bc3654a8eafaeff1c43e2b
First added on: Feb 08, 2025